When Lifesaving Vaccines Become Profit Machines for Drugmakers
July 6, 2021
Nicole Hassoun, Visiting Scholar
The drugmakers have “what everybody wants, and they can charge quite a bit,” says Nicole Hassoun, a professor at Binghamton University and visiting scholar at Cornell University. What level of profits is acceptable for makers of vaccines in the middle of the pandemic is a question that needs to be tackled, says Hassoun. “What’s clear is that they are going to make way, way more than their costs."